Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EPS (Weighted Average and Diluted) (2021 - 2023)

Terns Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.29 for Q4 2023.

  • For Q4 2023, EPS (Weighted Average and Diluted) fell 70.59% year-over-year to -$0.29; the TTM value through Dec 2023 reached -$1.27, up 25.73%, while the annual FY2025 figure was -$1.03, 8.04% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.29 in Q4 2023 per TERN's latest filing, up from -$0.42 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.17 in Q4 2022 to a low of -$0.63 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.41, with a median of -$0.43 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 72.9% in 2022, then plummeted 70.59% in 2023.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.63 in 2021, then surged by 72.9% to -$0.17 in 2022, then plummeted by 70.59% to -$0.29 in 2023.
  • Per Business Quant, the three most recent readings for TERN's EPS (Weighted Average and Diluted) are -$0.29 (Q4 2023), -$0.42 (Q3 2023), and -$0.25 (Q2 2023).